Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of FYX-051 in Hyperuricemia (with or without Gout)
jRCT2080221035Phase 3
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of topiroxostat in hyperuricemia, gout and nephrolithiasis, sponsored by Sanwa Kagaku Kenkyusho Co., Ltd.
02
Drugs
topiroxostat
03
Conditions
hyperuricemiagoutnephrolithiasis
Beyond the preview
Go deeper on jRCT2080221035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221035.